Table 3. Survival analyses comparison for main predictors.
| Predictors | 36-month rate | P-value |
| Progression free survival | ||
| Non-GCB1 (yes vs no) | 54.5% vs 85% | <.0001 |
| IgM-secreting (yes vs no) | 23.5% vs 75.7% | <.0001 |
| Immunoblastic Morphology (yes vs no) | 23.5% vs 75.7% | <.0001 |
| Anemia HB<12 g/dL (yes vs no) | 52.7% vs 80.7% | .001 |
| IPI2 (0–2 vs 3–5) | 52.8% vs 90.4% | <.0001 |
| ALC3 ≤0.840. 109/L (yes vs no) | 51.6% vs 75.3% | .003 |
| Bone marrow involvement (yes vs no) | 46.3% vs 79% | .001 |
| Overall survival | ||
| IgM-secreting (yes vs no) | 47.1% vs 74.8% | <.0001 |
| Immunoblastic Morphology (yes vs no) | 47.1% vs 74.8% | <.0001 |
| IPI (0–2 vs 3–5) | 56.9% vs 90.4% | <.0001 |
| ALC ≤0.840. 109/L (yes vs no) | 61.3% vs 76.5% | .022 |
| Bone marrow involvement (yes vs no) | 58.5% vs 76.5% | .024 |
Non-GCB1 = Non Germinal Center type, evaluated on the basis of the Hans' algorithm.
IPI2 = international prognostic index scores 0–2 and 3–5.
ALC3 = absolute lymphocyte count.